News
-
-
COMMUNIQUÉ DE PRESSE
Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Formycon extends CEO contract until 2027. Receives admission to trading in Frankfurt Stock Exchange's Prime Standard. Company's biosimilars contribute to healthcare accessibility and cost reduction -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
Formycon publishes study results in peer-reviewed journal analyzing biosimilar candidate FYB206 and Keytruda, showing high similarity in structure and function. Results support ongoing clinical trials -
-
